Skip to main content
Premium Trial:

Request an Annual Quote

Mitomics Realigns, Eliminates Eight Positions

NEW YORK (GenomeWeb News) – Mitochondrial DNA-based test developer Mitomics today announced a realignment of its product development operations, resulting in the elimination of eight jobs.

Chief Laboratory Officer Jennifer Creed will also now lead end-to-end product development for the company based in Thunder Bay, Ontario.

In a statement, Mitomics President and CEO Robert Poulter said that the firm "continues to face tremendous opportunity and potential for growth in the diagnostics arena."

The company's lead product is its Prostate Core Mitomic Test, or PCMT, launched in 2011 and conducted out of its CLIA-certified laboratory. Using existing biopsy tissue, the test identifies biomarkers that are associated with malignant cells in benign tissue. The firm is also developing tests for detecting breast cancer, bladder cancer, thyroid cancer, melanoma, ovarian cancer, pancreatic cancer, uterine cancer, and endometriosis, it said.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.